{
     "PMID": "21486038",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20110801",
     "LR": "20141120",
     "IS": "1520-4804 (Electronic) 0022-2623 (Linking)",
     "VI": "54",
     "IP": "9",
     "DP": "2011 May 12",
     "TI": "Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",
     "PG": "3206-21",
     "LID": "10.1021/jm101459g [doi]",
     "AB": "The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic beta(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.",
     "FAU": [
          "Bang-Andersen, Benny",
          "Ruhland, Thomas",
          "Jorgensen, Morten",
          "Smith, Garrick",
          "Frederiksen, Kristen",
          "Jensen, Klaus Gjervig",
          "Zhong, Huailing",
          "Nielsen, Soren Moller",
          "Hogg, Sandra",
          "Mork, Arne",
          "Stensbol, Tine Bryan"
     ],
     "AU": [
          "Bang-Andersen B",
          "Ruhland T",
          "Jorgensen M",
          "Smith G",
          "Frederiksen K",
          "Jensen KG",
          "Zhong H",
          "Nielsen SM",
          "Hogg S",
          "Mork A",
          "Stensbol TB"
     ],
     "AD": "Neuroscience Drug Discovery Denmark, H. Lundbeck A/S , 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark. ban@lundbeck.com",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20110412",
     "PL": "United States",
     "TA": "J Med Chem",
     "JT": "Journal of medicinal chemistry",
     "JID": "9716531",
     "RN": [
          "0 (Antidepressive Agents)",
          "0 (Piperazines)",
          "0 (Receptor, Serotonin, 5-HT2C)",
          "0 (Receptors, Serotonin)",
          "0 (Receptors, Serotonin, 5-HT1)",
          "0 (Receptors, Serotonin, 5-HT3)",
          "0 (Recombinant Proteins)",
          "0 (Serotonin 5-HT1 Receptor Agonists)",
          "0 (Serotonin 5-HT3 Receptor Antagonists)",
          "0 (Serotonin Plasma Membrane Transport Proteins)",
          "0 (Serotonin Uptake Inhibitors)",
          "0 (Sulfides)",
          "0 (serotonin 7 receptor)",
          "112692-38-3 (Receptor, Serotonin, 5-HT1A)",
          "333DO1RDJY (Serotonin)",
          "3O2K1S3WQV (vortioxetine)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Antidepressive Agents/*chemical synthesis/chemistry/pharmacology",
          "Cell Line",
          "Depressive Disorder, Major/*drug therapy",
          "Drug Partial Agonism",
          "Drug Stability",
          "Hippocampus/drug effects/metabolism",
          "Humans",
          "In Vitro Techniques",
          "Microsomes, Liver/metabolism",
          "Oocytes/drug effects/physiology",
          "Piperazines/*chemical synthesis/chemistry/pharmacology",
          "Radioligand Assay",
          "Rats",
          "Receptor, Serotonin, 5-HT1A/metabolism",
          "Receptor, Serotonin, 5-HT2C/metabolism",
          "Receptors, Serotonin/metabolism",
          "Receptors, Serotonin, 5-HT1/metabolism",
          "Receptors, Serotonin, 5-HT3/metabolism",
          "Recombinant Proteins/agonists/antagonists & inhibitors",
          "Serotonin/metabolism",
          "Serotonin 5-HT1 Receptor Agonists/chemical synthesis/chemistry/pharmacology",
          "Serotonin 5-HT3 Receptor Antagonists/chemical synthesis/chemistry/pharmacology",
          "Serotonin Plasma Membrane Transport Proteins/metabolism",
          "Serotonin Uptake Inhibitors/chemical synthesis/chemistry/pharmacology",
          "Structure-Activity Relationship",
          "Sulfides/*chemical synthesis/chemistry/pharmacology",
          "Xenopus"
     ],
     "EDAT": "2011/04/14 06:00",
     "MHDA": "2011/08/02 06:00",
     "CRDT": [
          "2011/04/14 06:00"
     ],
     "PHST": [
          "2011/04/14 06:00 [entrez]",
          "2011/04/14 06:00 [pubmed]",
          "2011/08/02 06:00 [medline]"
     ],
     "AID": [
          "10.1021/jm101459g [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.",
     "term": "hippocampus"
}